Table 1.
Demographics and baseline characteristics for participants who responded to treatment
| Characteristic | EM respondersa | CM respondersb | ||
|---|---|---|---|---|
| Quarterly fremanezumab (n = 214) |
Monthly fremanezumab (n = 215) |
Quarterly fremanezumab (n = 218) |
Monthly fremanezumab (n = 210) |
|
| Age, mean ± SD, y | 41.4 ± 11.7 | 43.1 ± 12.2 | 41.9 ± 12.7 | 41.3 ± 11.9 |
| Body mass index, mean ± SD, kg/cm2 | 26.9 ± 5.2 | 26.3 ± 5.4 | 26.7 ± 5.3 | 26.5 ± 5.0 |
| Male sex, n (%) | 29 (14) | 34 (16) | 22 (10) | 24 (11) |
| Race, n (%) | ||||
| White | 171 (80) | 178 (83) | 171 (78) | 171 (81) |
| Black/African American | 21 (10) | 17 (8) | 20 (9) | 16 (8) |
| Asian | 20 (9) | 18 (8) | 22 (10) | 21 (10) |
| Other | 2 (< 1) | 2 (< 1) | 5 (2) | 2 (< 1) |
| Disease history | ||||
| Years since initial migraine diagnosis, mean ± SD | 19.9 ± 11.9 | 20.5 ± 12.8 | 20.0 ± 12.6 | 19.8 ± 11.2 |
| Current preventive medication use, n (%) | 40 (19) | 44 (20) | 41 (19) | 45 (21) |
| Current use of acute headache medication, n (%) | 209 (98) | 212 (99) | 210 (96) | 199 (95) |
| Disease characteristics | ||||
| Monthly migraine days,c mean ± SD | 9.3 ± 2.5 | 9.1 ± 2.6 | 16.3 ± 4.6 | 16.0 ± 4.7 |
| Headache days of any severity,d mean ± SD | 8.5 ± 3.2 | 8.1 ± 3.2 | 15.5 ± 5.7 | 15.5 ± 5.5 |
| Monthly days of acute headache medication use, mean ± SD | 7.9 ± 3.6 | 7.9 ± 3.3 | 13.0 ± 6.6 | 13.3 ± 6.9 |
| MIDAS score | n = 201 | n = 205 | ||
| Mean ± SD, points | 39.2 ± 32.1 | 37.0 ± 33.4 | N/A | N/A |
| HIT-6 score | n = 204 | n = 202 | ||
| Mean ± SD, points | N/A | N/A | 64.3 ± 5.0 | 64.9 ± 4.5 |
| MSQoL domain score, mean ± SD, points | n = 211 | n = 212 | n = 215 | n = 208 |
| EF | 64.9 ± 23.2 | 65.5 ± 24.4 | 57.3 ± 26.4 | 58.3 ± 25.6 |
| RFP | 71.0 ± 17.9 | 71.7 ± 17.6 | 66.2 ± 21.1 | 67.3 ± 21.3 |
| RFR | 56.5 ± 16.3 | 57.3 ± 16.0 | 47.7 ± 18.6 | 49.0 ± 18.9 |
CM Chronic migraine, EF Emotional function, EM Episodic migraine, HIT-6 The 6-item Headache Impact Test, MIDAS Migraine Disability Assessment, MSQoL Migraine-Specific Quality of Life, N/A Not applicable, RFP Role function–preventive, RFR Role function–restrictive, SD Standard deviation, MAMD Monthly average migraine days
aResponders are defined as participants with EM who had a reduction of ≥2 MAMD
bResponders are defined as participants with CM who had a reduction of ≥4 MAMD
cA migraine day was defined as a calendar day in which headache pain lasted ≥4 consecutive hours and met criteria for migraine (with or without aura) or probable migraine (subtype in which only 1 migraine criterion is absent), or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any duration
dA headache day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and had a peak severity of at least a moderate level, or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any severity or duration